MYB and myelodysplastic syndrome: In our study, RSL3 decreased expression levels of MYB and Bcl-2, and RSL3 not only inhibited MDS cell proliferation as a single drug but also had synergistic effects with DAC to treat MDS cells, indicating promising clinical applications of RSL3 in the future.